metadata toggle
Clinical particulars
Target species
Indications for use
Treatment and prevention of flea infestation (Ctenocephalides felis).Efficacy against new infestations with fleas persists for 4 weeks following a single application.
The veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).
Developing stages of fleas in the pet’s immediate surroundings are killed following contact with Activyl treated pets.
Special warnings for each target species
The safety of Activyl has not been established in cats younger than 8 weeks of age.
The safety of Activyl has not been established in cats weighing less than 0.6 kg.
Special precautions for use
Special precautions for use in animals
Ensure that the dosage (pipette) corresponds to the weight of the treated cat.
Apply the product only to the skin surface and on intact skin. Apply the dose to an area where the cat cannot lick it off. Ensure that animals do not groom each other immediately following treatment. Keep treated animals separately until the application site is dry.
This product is for external topical application only. Do not administer orally or via any other route. Care should be taken to avoid the product coming into contact with the eyes of the cat.
The product remains effective following shampoo treatment, water immersion (swimming, bathing) and exposure to sunlight. However, animals should not be allowed to swim or treated with shampoo within 48 hours after treatment.
All cats in a household should be treated with a suitable flea product.
A proper treatment of the pet´s environment by additional chemical or physical measures is recommended.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Keep pipettes in the original packaging until ready to use.
Do not eat, drink or smoke while handling the veterinary medicinal product.
The sachet is child-resistant. Keep the product in the sachet until use, in order to prevent children from getting direct access to the product. Used pipettes should be disposed of immediately.
People with known hypersensitivity to indoxacarb should avoid contact with this product.
Local and/or systemic reactions have been observed in some people after exposure. To avoid adverse reactions:
• administer the product in a well-ventilated area;
• do not handle recently treated animals until the application site is dry;
• on the day of treatment, children must not handle treated animals and the animals should not be permitted to sleep with their owners, especially children;
• wash hands immediately after use and wash off any product in contact with the skin immediately with soap and water;
• avoid contact with eyes, as the product may cause moderate eye irritation. If it occurs, the eyes should be rinsed slowly and gently with water.
If symptoms occur, seek medical advice and show the package leaflet to the physician.
This product is highly flammable. Keep away from heat, sparks, open flame or other sources of ignition.
Adverse reactions
In rare cases, neurological signs (e.g. incoordination, tremor, ataxia, convulsions, mydriasis and impaired vision) have been observed. Other signs observed include emesis in rare cases or anorexia, lethargy, hyperactivity and vocalisation in very rare cases. All signs are generally reversible following supportive treatment.
In very rare cases, a brief period of hypersalivation may occur if the animal licks the application site immediately after treatment. This is not a sign of intoxication and disappears within some minutes without treatment. Correct application will minimise licking of the application site. In rare cases, application site reactions such as transitory scratching, erythema, alopecia or dermatitis at the application site may occur. These effects will usually resolve without treatment.
The application of the veterinary medicinal product may produce a local, temporary oily appearance or hair clumping at the application site. A dry white residue may be also observed. This is normal and will generally resolve within a couple of days after administration. These changes do not affect the safety or efficacy of the veterinary product.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals )
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports).
Use during pregnancy, lactation or lay
The safety of the veterinary medicinal product has not been established during pregnancy and lactation.
Do not use during pregnancy.
Do not use during lactation.
Do not use in breeding animals.
None known.
Amounts to be administered and administration route
Dosage schedule:
Cats: The recommended dose is 25 mg indoxacarb/kg body weight, equivalent to 0.128 ml/kg body weight. The following table defines the size of pipette to be used according to the weight of the cat:
Weight of cat (kg)
Pipette size
Volume (ml)
Indoxacarb (mg/kg)
< or equal to 4
Activyl Spot on for small cats
min 25
> 4
Activyl spot-on for large cats
Max 50
Method of administration:
For spot-on use only. Open one sachet and remove the pipette.
Step 1: The animal should be standing for easy application. With one hand, hold pipette in an upright position away from your face and with the other hand, snap tip open by bending it and folding it back on itself.
Step 2: Part the hair until the skin is visible and place pipette tip against the skin at the base of the skull, where the cat cannot lick it off. Squeeze pipette firmly applying the entire contents directly to the skin
Treatment schedule: Following a single administration, the veterinary medicinal product will prevent further flea infestation for at least 4 weeks.
No adverse effects were observed in cats aged 8 weeks or older when administered 5 times the recommended dose on 8 occasions at 4 weeks intervals or administered 5 times the recommended dose on 6 occasions at 2 weeks intervals.
Withdrawal periods
Not applicable